BACKGROUND: We examined safety and long-term outcomes of intravenous treprostinil administered via the implantable LENUS Pro pump in patients with severe pulmonary hypertension (PH). METHODS: Patients with PH undergoing pump implantation between December 2009 and October 2016 in German referral centers were retrospectively analyzed (end of follow-up: May 2017). The primary objective was to determine long-term safety of the implantable pump. Secondary end points were 3-year survival and prognostic relevance of pre-implantation hemodynamics. RESULTS: We monitored 129 patients (120 with pulmonary arterial hypertension, 1 with PH due to lung diseases, and 8 with inoperable chronic thromboembolic PH) for 260 patient-years (median follow-up, 19 m...
Background: Among patients with advanced pulmonary arterial hypertension (PAH) who are receiving epo...
BackgroundParenteral prostanoids are effective treatment for pulmonary arterial hypertension, but lo...
Abstract: Pulmonary arterial hypertension (PAH) is a progressive disease process with a high morbidi...
BACKGROUND: We examined safety and long-term outcomes of intravenous treprostinil administered via t...
Objectives Parenteral prostanoids infused via external pumps are well-established pulmonary arterial...
Abstract Background Subcutaneous treprostinil is a prostacyclin analogue used to treat pulmonary art...
BACKGROUND: Prostacyclins improve symptoms and survival in pulmonary arterial hypertension (PAH). In...
Background: The DelIVery for Pulmonary Arterial Hypertension clinical trial was a multi-center, pros...
Intravenous treprostinil administration by an implantable pump is an attractive option for pulmonary...
BACKGROUND: The use of systemic prostanoids in severe pulmonary arterial hypertension (PAH) is often...
BackgroundThe use of systemic prostanoids in severe pulmonary arterial hypertension (PAH) is often l...
Pulmonary arterial hypertension (PAH) is fatal if untreated. Intravenous epoprostenol improves exer...
Implantable infusion pumps might improve the convenience and safety of intravenous treprostinil for ...
Nika Skoro-Sajer1, Irene Lang1, Robert Naeije21Division of Cardiology, Department of Internal Medici...
ulmonary arterial hypertension (PAH) has traditionally been considered as an inevitably fatal diseas...
Background: Among patients with advanced pulmonary arterial hypertension (PAH) who are receiving epo...
BackgroundParenteral prostanoids are effective treatment for pulmonary arterial hypertension, but lo...
Abstract: Pulmonary arterial hypertension (PAH) is a progressive disease process with a high morbidi...
BACKGROUND: We examined safety and long-term outcomes of intravenous treprostinil administered via t...
Objectives Parenteral prostanoids infused via external pumps are well-established pulmonary arterial...
Abstract Background Subcutaneous treprostinil is a prostacyclin analogue used to treat pulmonary art...
BACKGROUND: Prostacyclins improve symptoms and survival in pulmonary arterial hypertension (PAH). In...
Background: The DelIVery for Pulmonary Arterial Hypertension clinical trial was a multi-center, pros...
Intravenous treprostinil administration by an implantable pump is an attractive option for pulmonary...
BACKGROUND: The use of systemic prostanoids in severe pulmonary arterial hypertension (PAH) is often...
BackgroundThe use of systemic prostanoids in severe pulmonary arterial hypertension (PAH) is often l...
Pulmonary arterial hypertension (PAH) is fatal if untreated. Intravenous epoprostenol improves exer...
Implantable infusion pumps might improve the convenience and safety of intravenous treprostinil for ...
Nika Skoro-Sajer1, Irene Lang1, Robert Naeije21Division of Cardiology, Department of Internal Medici...
ulmonary arterial hypertension (PAH) has traditionally been considered as an inevitably fatal diseas...
Background: Among patients with advanced pulmonary arterial hypertension (PAH) who are receiving epo...
BackgroundParenteral prostanoids are effective treatment for pulmonary arterial hypertension, but lo...
Abstract: Pulmonary arterial hypertension (PAH) is a progressive disease process with a high morbidi...